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Distinct families of multipotent heart progenitors play a central role in the generation of diverse cardiac, smooth 
muscle and endothelial cell lineages during mammalian cardiogenesis. The identification of precise paracrine signals 
that drive the cell-fate decision of these multipotent progenitors, and the development of novel approaches to deliver 
these signals in vivo, are critical steps towards unlocking their regenerative therapeutic potential. Herein, we have 
identified a family of human cardiac endothelial intermediates located in outflow tract of the early human fetal hearts 
(OFT-ECs), characterized by coexpression of Isl1 and CD144/vWF. By comparing angiocrine factors expressed by 
the human OFT-ECs and non-cardiac ECs, vascular endothelial growth factor (VEGF)-A was identified as the most 
abundantly expressed factor, and clonal assays documented its ability to drive endothelial specification of human 
embryonic stem cell (ESC)-derived Isl1
+ progenitors in a VEGF receptor-dependent manner. Human Isl1-ECs (en-
dothelial cells differentiated from hESC-derived ISL1
+ progenitors) resemble OFT-ECs in terms of expression of the 
cardiac endothelial progenitor- and endocardial cell-specific genes, confirming their organ specificity. To determine 
whether VEGF-A might serve as an in vivo cell-fate switch for human ESC-derived Isl1-ECs, we established a novel 
approach using chemically modified mRNA as a platform for transient, yet highly efficient expression of paracrine 
factors in cardiovascular progenitors. Overexpression of VEGF-A promotes not only the endothelial specification but 
also engraftment, proliferation and survival (reduced apoptosis) of the human Isl1
+ progenitors in vivo. The large-
scale derivation of cardiac-specific human Isl1-ECs from human pluripotent stem cells, coupled with the ability to 
drive endothelial specification, engraftment, and survival following transplantation, suggest a novel strategy for vas-
cular regeneration in the heart.
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Introduction
Unraveling the cardiogenic cell-fate map and the sig-
naling pathways that control the formation of diverse car-
diac muscle, smooth muscle and endothelial lineages is 
central to our understanding of the etiology of adult and 
congenital heart disease, as well as in the search for nov-
el regenerative therapeutic strategies. Although signifi-
cant progress has been made toward elucidating the path-
ways that drive cardiomyocyte (CM) lineages (reviewed 
in [1]), relatively less is known about the origins of the 
distinct endothelial cell (EC) lineages that constitute the 
coronary arterial, venous and endocardial compartments www.cell-research.com | Cell Research
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of the heart. Cumulative studies from the zebrafish [2, 3], 
chick [4, 5], mouse [6-8] and human [9] models have re-
vealed a heterogeneous origin of the endothelial lineages 
in the heart, and have recently indicated that a subset of 
these ECs are derived from a distinct origin of multipo-
tent heart progenitors located in various specific regions 
of the early heart field [10, 11]. 
During vertebrate gastrulation, cardiovascular progen-
itors located in the anterior region of the primitive streak 
migrate anteriorlaterally to form bilateral heart fields, 
also known as the cardiac crescent [12]. As the embryo 
folds ventrally, the two heart fields coalesce into a linear 
heart tube. The second heart field (SHF) contains pro-
genitors initially located outside the heart within the pha-
ryngeal mesoderm, which then migrate into the heart and 
give rise to the endocardium, myocardium, pacemaker 
and smooth muscle lineages (reviewed in [13]). In the 
lineage tracing Isl1-cre;R26R mouse model, it has been 
demonstrated that Isl1 marks cell populations that con-
tribute to subsets of ECs in myocardium and aortic endo-
thelium [11, 14]. Coexpression of Isl1 and CD31 in cells 
can be observed within the outflow tract at E11.5 [15]. 
Moreover, using the genetic fate-mapping studies in both 
murine [11] and human [16] embryonic stem cells (ESCs), 
the Isl1
+ progenitors can be isolated and clonally ampli-
fied, which resemble the developmental cardiovascular 
progenitors in the murine embryonic and human fetal 
hearts, respectively. The murine or human ESC-derived 
Isl1
+ progenitors give rise to three distinct cardiovascular 
cell lineages, namely CMs, smooth muscle cells (SMCs) 
and ECs. These studies, primarily performed in vitro, 
further support that Isl1
+ progenitors can differentiate 
toward an EC fate, and raise the necessity to identify the 
precise paracrine signals that drive this decision. 
In this study, we have examined the specific develop-
mental stimulus that supports the endothelial specifica-
tion of the human Isl1
+ progenitors in vitro and in vivo. 
By screening angiocrine factors expressed in ECs derived 
from the outflow tract (OFT-ECs) of human fetal hearts 
compared with that in outgrowth ECs (OECs) derived 
from human cord blood, vascular endothelial growth 
factor (VEGF)-A (165) was found to be the most abun-
dantly expressed angiocrine factor that could direct the 
differentiation of the human ESC-derived Isl1
+ progeni-
tors toward an EC fate and away from the more sponta-
neously differentiated SMC lineage. Moreover, we have 
also identified the developmental counterpart of the Isl1-
ECs in human fetal hearts. The Isl1
+ endothelial interme-
diates, marked as Isl1
+CD144
+ or Isl1
+vWF
+, were iden-
tified in the outflow tract (OFT) region of human fetal 
hearts at gestation week 9. To address the longstanding 
question regarding cell-fate specification of the human 
ESC-derived Isl1
+ progenitors in vivo, we have employed 
a novel approach to overexpress VEGF-A in the Isl1
+ 
progenitors via chemically modified mRNA (modRNA). 
We have demonstrated that VEGF-A promotes an EC 
fate decision of the human Isl1
+ progenitors in vitro and 
in vivo, away from the SMC lineage, as well as facilitat-
ing the proliferation and survival (reduced apoptosis) of 
the Isl1
+ progenitors. These studies suggest that VEGF-A 
is a switch that controls the cell-fate specification of mul-
tipotent human heart progenitors, and that in vitro trans-
fection of heart progenitors prior to transplantation can 
enhance their engraftment and survival, adding a new 
potential role of VEGF-A modRNA in addition to recent 
studies showing its ability in driving heart regeneration 
following myocardial infarction (MI) [17]. 
Results
Human Isl1
+ endothelial progenitors, found in the out-
flow tract region of the early human fetal hearts, express 
VEGF receptors 1 and 2 
Our laboratory has reported previously that Isl1-ECs 
can be found in aorta/OFT region of embryonic hearts of 
the Isl1-cre;R26R;LacZ mice [11]. To evaluate whether 
Isl1-ECs can be found in human hearts, frozen sections 
of human fetal hearts at gestation week 9 were co-stained 
for Isl1 and EC-specific markers CD144 or vWF (Figure 
1A). The Isl1
+CD144
+ and Isl1
+vWF
+ cells, found in the 
lower portion of the OFT septum, may represent the Isl1
+ 
endothelial intermediates as described previously [18]. 
Moreover, the Isl1
+ cells were also found positive for the 
VEGF-A receptors, VEGFR1 (Flt1) and KDR (Figure 
1A). Using the lineage-tracing human Isl1-cre eGFP 
ESC line, in which CRE has been knocked into the Isl1 
locus, one can trace the cell fate as the daughter cells of 
the Isl1
+ lineage are marked as eGFP
+ (Figure 1B), and 
the human ESC-derived Isl1
+ progenitors (eGFP
+) can 
also be purified following direct differentiation of ESCs 
using BMP4, Activin A and FGF2 (Figure 1C). Intrigu-
ingly, not only the Isl1
+ cells of human fetal hearts, but 
also the Isl1
+ progenitors derived from hESCs also ex-
pressed both Flt1 and KDR (Figure 1D). Approximately 
98% (4.5% out of 4.6% total eGFP
+ cells) and 9% (0.5% 
out of 5.3% total eGFP
+ cells) of the human ESC-derived 
Isl1
+ progenitors expressed Flt1 and KDR, respectively, 
on day 7 of differentiation (Figure 1D). Our result is in 
line with a previous report that identified low expression 
level of KDR but higher expression level of Flt1 in en-
docardial ECs [19]. Furthermore, expression of the Isl1 
gene could be found in the Flt1
+ or KDR
+ cells during 
human ESC differentiation (Supplementary information, 
Figure S1A). Since Isl1 is also known to be expressed VEGF-A mRNA promotes cell-fate switch of heart progenitors
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Figure 1 Expression of VEGF receptors in the human Isl1
+ progenitors. (A) Frozen sections from a human fetal heart at 
gestation week 9 were stained for DAPI (scale bar = 500 µm), Isl1, endothelial cell-specific markers: CD144, vWF, VEGF-
A receptor 1 (Flt1) or 2 (KDR), or neurofilament (scale bars = 50 µm and 10 µm). Isl1
+ cells are indicated by white asterisks 
(scale bar = 100 µm) and colocalization of Isl1 and EC markers are indicated by white arrows (scale bar = 10 µM). (B) Sche-
matic diagram showing the Isl1 lineage-tracing construct in human ESCs. (C) Differentiation protocol used to derive the Isl1
+ 
progenitors from human ESCs and to examine, which angiocrine factor (X) is responsible for endothelial differentiation of the 
progenitors. (D) FACS analyses showing expression of VEGFR1 or VEGFR2 in day-4 or day-7 human Isl1
+ progenitors.www.cell-research.com | Cell Research
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in cardiac ganglia [15], co-staining of Isl1 and neurofila-
ment was also performed (Figure 1A). Our result indicat-
ed that the Isl1
+ cells, and, therefore, the Isl1
+ endothelial 
intermediates identified in the same OFT region of hu-
man fetal hearts were negative for neurofilament.   
VEGF-A is the most abundantly expressed angiocrine 
factor by cardiac ECs and is sufficient to drive endothe-
lial differentiation of the human Isl1
+ progenitors 
To elucidate the candidate angiocrine factor respon-
sible for endothelial specification of the human Isl1
+ 
progenitors, quantitative PCR (qPCR) arrays were per-
formed to compare the gene expression levels of angio-
crine factors between the human cardiac OFT-ECs and 
human noncardiac EPCs such as OECs. In general, OFT-
ECs express more angiocrine factors than OECs (Figure 
2A and Supplementary information, Figure S2). VEGF-A 
was not only the most abundantly expressed angiocrine 
factor by OFT-ECs among the 82 factors tested (Figure 
2A), but also the most abundantly expressed ligand of the 
VEGF family by ECs derived from different subdomains 
of human fetal hearts at gestation weeks 10 (Supplemen-
tary information, Figure S1B) and 20 (Supplementary 
information, Figure S1C), whereas PLGF was the most 
abundantly expressed ligand of the VEGF family by non-
cardiac OECs (Supplementary information, Figure S1B 
and S1C). 
By transplanting the human Isl1-cre eGFP
+ embry-
oid bodies (EBs) under the kidney capsule of nonobese 
(NOD)/severe combined immunodeficient (SCID) mice, 
it appears that the Isl1
+ progenitors spontaneously dif-
ferentiated into eGFP
+SMMHC
+ smooth muscle-like 
and eGFP
+cTNT
+ cardiac muscle-like lineages in vivo 
(Supplementary information, Figure S3A); however, 
eGFP
+CD31
+ endothelial-like cells were not observed in 
any of the recipients (n = 5, data not shown). Therefore, 
exogenous signal(s) seem to be needed in directing dif-
ferentiation of the human Isl1
+ progenitors toward the en-
dothelial lineage and away from the more spontaneously 
differentiated smooth muscle and cardiac muscle lineag-
es. To examine which angiocrine factor might be respon-
sible for endothelial specification of the human Isl1
+ pro-
genitors, angiocrine factors that were highly expressed 
by OFT-ECs were employed as “X” in the endothelial 
differentiation protocol (Figure 1C). Among the top 
eight angiocrine factors that were highly expressed by 
OFT-ECs, VEGF-A was the most abundantly expressed 
one that could drive differentiation of the day-7 purified 
eGFP
+ cells (Isl1
+ progenitors) into eGFP
+CD31
+CD144
+ 
cells (Isl1-ECs, Figure 2B). To confirm the tri-lineage 
differentiation potential of hESC-derived Isl1
+ pro-
genitors by VEGF-A, day-7 purified eGFP
+ cells were 
replated as single cells with or without VEGF-A for 
10 days (Supplementary information, Figure S3B). 
eGFP
+SMMHC
+ smooth muscle-like and eGFP
+cTNT
+ 
cardiac muscle-like cells were found in both groups, 
whereas eGFP
+CD31
+ endothelial-like cells were found 
in the VEGF-A-treated group only. Furthermore, up-
regulation of the Cd31 gene, but downregulation of the 
Smmhc
 and cTnt genes was observed following treat-
ment with VEGF-A compared with the untreated control 
group (Supplementary information, Figure S3C). Taken 
together, our results from the in vivo transplantation and 
in vitro cell clonal assays support that the day-7 purified 
eGFP
+ cells can differentiate into SMs, CMs or ECs; and 
VEGF-A is needed to drive endothelial differentiation of 
the human Isl1
+ progenitors. Furthermore, in addition to 
our previous report that showed coexpression of Isl1 and 
CD31 in human fetal hearts at gestation week 11 [16], 
our results show that CD144 seems to be an earlier and 
more readily expressed EC marker for Isl1
+ endothelial 
intermediates compared to CD31. Expression of CD144 
was detected as early as on day 7 in the differentiated 
human ESC-derived Isl1
+ progenitors (eGFP
+) (Supple-
mentary information, Figure S3C, top right panel). Using 
both CD31 and CD144, we could purify a more discrete 
population of ECs from the ESC differentiation cultures.
Endothelial differentiation of the human Isl1
+ progeni-
tors is KDR dependent
In addition to its capability of directing endothelial 
differentiation, VEGF-A could also expand the eGFP
+ 
progenitors from 35.6% to 43.8% following treatment 
from day 4-7 in the differentiation cultures (Figure 2C 
top panels). In general, directing differentiation of the 
day-7 purified eGFP
+ progenitors by VEGF-A can yield 
approximately 8-10% eGFP
+CD31
+CD144
+ cells in 7 
days of differentiation (D14, n = 25, Figure 2C bottom 
panels, Supplementary information, Figure S3C). As 
demonstrated in a cell clonal assay (Figure 2D), cultur-
ing the day-7 purified eGFP
+ progenitors on irradiated 
murine embryonic fibroblasts (MEF), a condition main-
taining the self-renewing capacity of the multipotent 
Isl1
+ progenitors [16], in the presence of VEGF-A for 5 
days upregulated expression of the SHF progenitor gene, 
Isl1 (P < 0.01), cardiac EC gene [20], Wt1 (Wilm’s tu-
mor gene-1, P < 0.05), and EC-specific gene, Cd31 (P < 
0.005), compared with the untreated control (n = 33). To 
examine whether the effect of VEGF-A on endothelial 
differentiation of the human Isl1
+ progenitors is depen-
dent on its receptor VEGFR2 (KDR), a KDR inhibitor 
(SU5614) was used in addition to VEGF-A in differenti-
ating the day-7 purified eGFP
+ progenitors from day 7-14 
(Figure 2C bottom panels). As SU5614 is known to in-VEGF-A mRNA promotes cell-fate switch of heart progenitors
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Figure 2 VEGF-A is the most abundantly expressed angiocrine factor in human fetal hearts and endothelial differentiation of 
the human Isl1
+ progenitors is KDR dependent. (A) qPCR profiling showing expression levels of angiocrine factors derived 
from CD144
+CD31
+ ECs purified from outflow tract of the 10-week human fetal hearts, expression levels were compared with 
those of the noncardiac, human cord blood-derived outgrowth endothelial cells (OECs, value on y axis = 1). (B) FACS analy-
ses to determine the endothelial differentiation efficiency by factor X following treatment from day 7-12. (C) FACS analyses 
on the proliferation rate of the human Isl1-cre eGFP
+ cells following VEGF-A treatment from day 4-7, and the endothelial dif-
ferentiation efficiency without VEGF-A, with VEGF-A or with VEGF-A+KDR inhibitor (SU5614) from day 7-14. (D) Clonal as-
say was performed by culturing the day-7 human Isl1-cre eGFP
+ cells on MEFs with VEGF-A (n = 33) for 3 days. Result was 
normalized to cells without VEGF-A treatment. (E) qPCR data showing endothelial differentiation of the day-7 human Isl1-cre 
eGFP
+ cells in the presence of VEGF-A or VEGF-A+SU5614 for 7 days. Result was normalized to cells with VEGF-A alone 
(value on y axis =1). www.cell-research.com | Cell Research
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duce apoptosis, only PI
− viable cells were taken into ac-
count during analyses. Treatment of SU5614 reduced the 
eGFP
+CD31
+CD144
+ population from 10.8% (VEGF-A 
alone) to 0.93% (VEGF-A + SU5614), which was com-
parable to the untreated control (0%). Moreover, SU5614 
downregulated the gene expression of Cd31 (P < 0.01) 
and endothelial-specific nitric oxide synthase (eNos, P < 
0.005), compared with the VEGF-A alone group (expres-
sion level = 1, Figure 2E). 
Human Isl1-ECs resemble cardiac endothelial progeni-
tors
To confirm an endothelial phenotype of the purified 
eGFP
+CD31
+CD144
+ cells, FACS analyses were per-
formed to demonstrate their surface expression of the en-
dothelial markers (Figure 3A), including CD34 (99.5%), 
CD105 (67.9%), CD117 (89.2%), FLT1 (71.6%), KDR 
(67.6%) and FLT4 (99.2%). A small population of the 
eGFP
+CD31
+CD144
+ cells also expressed CD133 and 
CXCR4. Moreover, qPCR was performed to evaluate ex-
pression levels of transcription factors specific for EPCs 
or endocardial ECs. Our result shows that OECs, OFT-
ECs (gestation week 10 or 20) and eGFP
+CD31
+CD144
+ 
cells (Isl1-ECs D14 or D28) expressed higher levels of 
endothelial progenitor genes, including Etv2, Foxc1, 
Hoxa9 and Id1, compared with the adult human cardiac 
microvascular ECs (HMVEC-c) (Supplementary infor-
mation, Figure S4A). Moreover, OFT-ECs (gestation 
week 10 or 20) and eGFP
+CD31
+CD144
+ cells (Isl1-ECs 
D14 or D28), but not the day-7 purified eGFP
+ cells (Isl1 
progenitors), expressed the endocardial EC genes such as 
Nfatc-1, Connexin 43 and Connexin 45 (Supplementary 
information, Figure S4B). 
To confirm the cardiac origin of the purified 
eGFP
+CD31
+CD144
+ cells, qPCR was performed to eval-
uate expression levels of the cardiac progenitor genes 
compared with those of the non-cardiac OECs. Our result 
shows that both the OFT-ECs (gestation week 10 or 20) 
and eGFP
+CD31
+CD144
+ cells (D14 or D28) expressed 
higher levels of Isl1, Tbx20, Nkx2.5, Gata4, Tbx1, Tbx5 
and Mef2c genes compared with the noncardiac OECs 
(Supplementary information, Figure S4C and S4D). Fur-
thermore, expression patterns of angiocrine genes were 
compared among day-7 puified eGFP
+ progenitors, day-
14 purified eGFP
+CD31
+CD144
+ cells (Isl1-ECs), OFT-
ECs (gestation week 10) and OECs by qPCR arrays. Our 
results show that the expression pattern of angiocrine 
genes between the Isl1 progenitors and Isl1-ECs was 
comparable (Figure 3B and 3C); and the expression pat-
tern of angiocrine genes of Isl1-ECs was more similar to 
that of the cardiac OFT-ECs (34 in common, Figure 3B) 
than that of the noncardiac OECs (8 in common, Figure 
3C). To evaluate EC functions, tube formation and secre-
tion of nitric oxide (NO) were evaluated in vitro. Our 
results show that the purified eGFP
+CD31
+CD144
+ cells 
formed 3-dimentional tube structures in matrigel (Sup-
plementary information, Figure S5A and S5B). More-
over, expression of eNOS was found in all of the purified 
eGFP
+CD31
+CD144
+ cells (Supplementary information, 
Figure S5C), and secretion of NO was also detected at a 
comparable level between the eGFP
+CD31
+CD144
+ cells 
and OECs. (Supplementary information, Figure S5D). 
To evaluate the potential of endothelial-to-mesenchymal 
transition (EndoMT) of the eGFP
+CD31
+CD144
+ cells, 
TGF-β was added in EC cultures as described previously 
[21, 22]. Upregulation of mesenchymal cell-associated 
genes (α-SMA and Sm22) was detected in the TGF-β-
treated-eGFP
+CD31
+CD144
+ cells compared with the 
untreated controls (Supplementary information, Figure 
S5E).
VEGF-A modRNA can drive endothelial differentiation 
of the human Isl1
+ progenitors
To further examine the role of VEGF-A in driving 
endothelial differentiation of the human Isl1
+ progeni-
tors, a novel modRNA approach [23, 24] was utilized to 
mediate highly efficient expression of autocrine proteins 
in these progenitors. We first examined the expression ki-
netics of a reporter modRNA transfected into the human 
Isl1
+ progenitors in vitro. mCherry modRNA (1 µg/10
6 
cells) was transfected into the day-7 purified eGFP
+ 
progenitors, and expression of the mCherry protein was 
evaluated at 3-150 h post-transfection. Our result shows 
that the expression level of mCherry peaked at 18-24 h 
with approximately 90% cells being transfected (Figure 
4A and Supplementary information, Figure S6), and then 
returned to the basal level 140 h post-transfection (Figure 
4B). Similarly, a time-dependent response was observed 
following transfection of eGFP
+ cells with the VEGF-A 
modRNA (Figure 4C). To quantify protein secretion and 
survival of the transfected eGFP
+ cells, supernatants and 
cells were assayed, respectively, at different time points 
following transfection of 10
6 cells with 0.5, 1, 2, 3 or 5 
µg of VEGF-A modRNA. A dose-dependent response 
was observed (Figure 4C) and > 80% survival could 
be found following in vitro transfection with ≤ 1 µg of 
VEGF-A modRNA (Figure 4D); however, > 30% cell 
death was observed following transfection with ≥ 2 µg 
of VEGF-A modRNA (Figure 4D). To evaluate whether 
repeated transfections with the VEGF-A modRNA can 
drive endothelial differentiation of the human Isl1
+ pro-
genitors as efficiently as the use of recombinant protein 
in vitro, protein secretion by the transfected eGFP
+ cells 
was assayed at different time points following transfec-VEGF-A mRNA promotes cell-fate switch of heart progenitors
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Figure 3 VEGF-A-treated human Isl1
+ progenitors express EC markers and secrete angiocrine factors in a similar pattern to 
the human outflow tract-derived ECs. (A) FACS analyses on the purified CD144
+CD31
+ ECs from the human Isl1-cre eGFP
+ 
cells (Isl1-ECs) in the presence of VEGF-A from day 7-21. (B, C) Correlation of angiocrine gene expression between qPCR 
data obtained from the day-7 purified human Isl1-cre eGFP
+ cells (Isl1 progenitors) or Isl1-ECs in the presence of VEGF-A 
from day 7-21 and (B) the purified CD144
+CD31
+ ECs from the outflow tract of human fetal hearts at 10 weeks of gestation 
(OFT-ECs) or (C) the noncardiac, human cord blood-derived outgrowth endothelial cells (OECs) (n = 5). www.cell-research.com | Cell Research
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tion with the VEGF-A modRNA (1 µg/10
6 cells, me-
dium was refreshed 6 h before collection). Our results 
show that the highest expression level of VEGF-A can 
be maintained through daily transfections (Figure 4E); 
however, the accumulated VEGF-A protein is stable for 
at least 3 days in culture as assayed by ELISA (data not 
Figure 4 Endothelial differentiation of the human Isl1
+ progenitors can be achieved by repeated transfections of the VEGF-A 
modRNA. (A) FACS result showing expression of mCherry in the day-7 purified human Isl1-cre eGFP
+ cells 24 h post trans-
fection of the mCherry modRNA (1 µg/10
6 cells). (B) Quantification of mCherry expression by FACS showing percentage of 
mCherry
+ Isl1-cre eGFP
+ cells following 0-150 h post transfection. (C) ELISA analyses using VEGF-A-containing supernatant 
(refreshed 6 h before collection) cultured with the day-7 purified human Isl1-cre eGFP
+ cells following 0-72 h post transfec-
tion of different concentrations of the VEGF-A modRNA. (D) Trypan blue staining showing the survival percentage of the day-
7 purified human Isl1-cre eGFP
+ cells following 24 h post transfection of different concentrations of the VEGF-A modRNA. 
(E) ELISA analyses showing the rate of VEGF-A secreted by the day-7 purified human Isl1-cre eGFP
+ cells (supernatant 
refreshed 6 h before collection) following two rounds of daily transfections of 1 µg/10
6 cells with VEGF-A modRNA. (F) FACS 
analyses showing the efficiency of CD144
+CD31
+ EC differentiation by one transfection or repeated transfections (following 
medium change) of the VEGF-A modRNA compared to the use of VEGF-A protein 3 or 7 days post treatment.VEGF-A mRNA promotes cell-fate switch of heart progenitors
1180
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Figure 5 VEGF-A drives differentiation of the human Isl1
+ progenitors toward an EC lineage, but away from the SMC lineage 
in vivo. (A) Schematic diagram of the experimental design. (B-U) Frozen sections from matrigel plugs incubated with the day-
7 purified human Isl1-cre eGFP
+ cells in the presence of (B-K) vehicle or (L-U) VEGF-A modRNA were stained for eGFP with 
smooth muscle- or endothelial cell-specific markers (scale bar in C = 100 µm, scale bar in M = 50 µm, scale bars in all the 
remaining panels = 25 µm). (V) Quantification analyzed by ImageJ showing number of double positive cells (eGFP
+SMMHC
+, 
eGFP
+Vimentin
+ or eGFP
+CD31
+) per unit area of the matrigel plug following treatment with vehicle or VEGF-A modRNA. www.cell-research.com | Cell Research
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shown), thus repeated transfections may be needed only 
when the culture medium was refreshed. Approximately 
8-10% eGFP
+CD31
+CD144
+ cells were differentiated 
from the day-7 purified eGFP
+ progenitors following re-
peated transfections, which was comparable to the use of 
recombinant VEGF-A protein (n = 5, Figure 4F). 
VEGF-A modRNA promotes cell-fate shift, proliferation 
and survival (reduced apoptosis) of the human Isl1
+ pro-
genitors in vivo
To examine the role of VEGF-A in driving endothelial 
differentiation of the human Isl1
+ progenitors in vivo, 
day-7 purified eGFP
+ progenitors were implanted sub-
cutaneously (s.c.) in the vehicle- or VEGF-A modRNA-
containing matrigel in NOD/SCID mice for 2 weeks 
(Figure 5A). Frozen sections of the vehicle- or VEGF-
A modRNA-treated matrigel plugs were stained for the 
SMC (SMMHC, Vimentin), EC (CD31), or CM (cTNT) 
markers. Our immunostaining results reveal that there 
were more eGFP
+SMMHC
+ (Figure 5C-5E vs 5M-5O) 
or eGFP
+Vimentin
+ (Figure 5F-5H vs 5P-5R) smooth 
muscle-like structures (Figure 5B) in the vehicle-treated 
than the VEGF-A modRNA-treated group (Figure 5V), 
whereas there were more eGFP
+CD31
+ (Figure 5S-5U 
vs 5I-5K) microvessel-like structures (Figure 5L) in 
the VEGF-A modRNA-treated than the vehicle-treated 
group (Figure 5V). No eGFP
+cTNT
+ cells were observed 
in both groups (data not shown). Furthermore, we em-
ployed matrigel cytometry to quantify angiogenesis as 
previously described [25]. Matrigel provides an immedi-
ate source of growth factors and nutrients for EC differ-
entiation and, therefore, a subset of eGFP
+CD31
+CD144
+ 
population can be found in the vehicle-treated group. 
Importantly, our data reveals that there was an increase 
in the eGFP
+CD31
+CD144
+ population from 6.46% 
in the vehicle-treated group to 16.4% in the VEGF-
A modRNA-treated group (Figure 6A), indicating that 
VEGF-A can indeed drive differentiation of the human 
Isl1
+ progenitors into Isl1-ECs in vivo. By calculating 
the number of eGFP
+ cells isolated from the matrigel 
plugs, our data show that approximately 20 and 5% of 
the original implanted eGFP
+ cells could be recovered in 
the modRNA-treated and vehicle-treated matrigel plugs, 
respectively (Figure 6C). To evaluate why a greater 
number of eGFP
+ cells could be harvested from the mo-
dRNA-treated group, frozen sections of the vehicle- or 
VEGF-A modRNA-treated matrigel plugs were stained 
for Ki67 and Tunel (Figure 6B). There were more pro-
liferating eGFP
+Ki67
+ (P < 0.05, n = 5) and less apop-
totic eGFP
+Tunel
+ (P < 0.05, n = 5) cells in the VEGF-A 
modRNA-treated group than the vehicle control group. 
Taken together, our results reveal that VEGF-A not only 
promotes endothelial specification of the Isl1
+ progeni-
tors but also contributes to increased proliferation and 
reduced apoptosis of their daughter cells in vivo.
Discussion
Isl1
+ endothelial progenitors and their intermediates in 
human cardiogenesis
The generation of diverse cardiac, smooth muscle and 
EC lineages in distinct compartments of the human heart 
is based on the expansion of multipotent cardiovascular 
progenitors and the formation of a diverse subset of cel-
lular intermediates (reviewed in [18]). In contrast to the 
murine hearts, in many cases, these human cardiovas-
cular intermediates coexpress early progenitor markers 
(e.g., Isl1), as well as differentiated markers (e.g., cTnT 
or SMMHC), suggesting that they are already commit-
ted towards a defined cardiac or SMC lineage [16]. In 
the current study, we have identified subsets of the Isl1-
expressing endothelial intermediates (Isl1
+CD144
+ or 
Isl1
+vWF
+) in OFT region of the early human fetal hearts 
(gestation week 9), in addition to the previously reported 
human Isl1-expressing smooth muscle and cardiac myo-
cyte intermediates [16]. Moreover, we have employed a 
well-characterized human ESC line that harbors a knock-
in of Cre recombinase in the Isl1 locus, allowing lineage 
tracing of the downstream cellular intermediates. By 
sorting for the GFP reporter driven by the Cre recombi-
nase expression and the differentiated EC surface mark-
ers such as CD144 and CD31, we were able to purify 
human cardiac-specific endothelial progenitors and to 
characterize them at transcriptional, translational and 
functional levels in vitro and in vivo.
In this study, we defined a comprehensive cardio-
vasculogenic signature of Isl1-ECs using FACS, im-
munostaining and transcriptional approaches. Isl1-ECs 
expressed protein markers previously defined as puta-
tive EPCs (CD34, CD105, CD117 and CD133) and ECs 
(CD31, CD144, eNOS, VEGFR1/2/3 and vWF). There 
is no known transcription factor expressed exclusively 
in EPCs or ECs [26]. Previous studies have shown that 
Id1 and Id3 double knockout [27], Foxc1
−/− [28], Etv2
−/− 
[29, 30] and Hoxa9-deficient [31] mice have severe 
vascular defects. Consistent with previous findings, 
Isl1-ECs expressed Id1, Foxc1, Etv2 and Hoxa9, which 
are indicators of EPC development and/or EC lineage 
commitment. Moreover, Isl-ECs upregulated cardiac-
specific genes, including Gata4, Isl1, Mef2c, Nkx2.5, 
Tbx1, Tbx5 and Tbx20, compared with the noncardiac 
OECs. Intriguingly, Isl1-ECs also expressed Wt1, which 
is a cardiac-specific endothelial progenitor marker [20, 
32]. Nevertheless, more studies are needed to elucidate VEGF-A mRNA promotes cell-fate switch of heart progenitors
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Figure 6 VEGF-A drives endothelial differentiation and promotes survival via increased proliferation and reduced apoptosis of 
the human Isl1
+ progenitors in vivo. (A) FACS analyses to determine the percentage of CD144
+CD31
+ ECs differentiated from 
the human Isl1-cre eGFP
+ cells isolated from matrigel plugs following incubation in the presence of vehicle or VEGF-A mo-
dRNA 2 weeks post s.c. implantation. (B, C) Cell counting to determine the percentage of proliferation (eGFP
+Ki67
+ by immu-
nostaining), apoptosis (eGFP
+Tunel
+ by immunostaining) or survival (total eGFP
+ cells by FACS) of the human Isl1-cre eGFP
+ 
cells in the vehicle- or VEGF-A modRNA-treated matrigel plugs two weeks post s.c. implantation. (D) Model for the proposed 
cell fate switch of the human Isl1
+ progenitors following VEGF-A treatment.www.cell-research.com | Cell Research
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the molecular, cellular phenotypes and functional proper-
ties of cardiac-specific ECs compared with ECs in other 
organ systems.
VEGF-A is an endothelial cell-fate switch for multipotent 
heart progenitors
Although in vivo lineage tracing during murine car-
diogenesis was able to indicate that a substantial portion 
of ECs in the mammalian heart are derived from the Isl1
+ 
heart progenitors [11], a direct demonstration in human 
hearts via clonal assays was found difficult due to inef-
ficient differentiation of the Isl1
+ progenitors toward the 
endothelial lineage. In our experience, Isl1
+ progenitors 
isolated from murine embryos and ESCs, or human ESCs 
appeared to differentiate spontaneously into SMCs and, 
to some extent, CMs. Indeed, by transplanting the Isl1-
expressing EBs under the kidney capsule of NOD/SCID 
mice, Isl1
+ progenitors differentiated spontaneously into 
smooth muscle- or cardiac muscle-like cells. Although 
the Isl1-derived SMCs, CMs and ECs can be found in the 
Isl1-cre;R26R murine hearts [11], exogenous signals are 
needed to drive endothelial differentiation of the progeni-
tors away from the more spontaneously differentiated 
smooth muscle and cardiac muscle lineages. 
A recent study has documented that ventricular endo-
cardial cells are capable of forming the coronary arteries 
by angiogenesis through myocardial-endothelial VEGF 
signaling [8]. In fact, CMs but not ECs provide the major 
source of VEGF [33], indicating the importance of para-
crine signaling in facilitating blood vessel development 
in the heart. In this study, we report that a single para-
crine factor VEGF-A can drive endothelial differentia-
tion of the multipotent Isl1
+ progenitors both in vitro and 
in vivo. By ablating Flk1 in the Isl1-cre mice, a reduction 
in the number of Isl1-ECs was observed in the endocar-
dium [6], suggesting that Flk1 is required for the forma-
tion of the endocardium. Our result is consistent with 
the previous murine study that KDR was required for 
the VEGF-A-induced endothelial differentiation of the 
human Isl1
+ progenitors. Although the loss of Isl1-ECs 
in the endothelium of Isl-cre;Flk1 null mice is replaced 
by vascular ECs [6], we are unsure whether such a com-
pensational growth is sufficient to compensate for func-
tions of the organ-specific ECs. We found that cardiac 
ECs expressed more angiocrine factors than noncardiac 
vascular progenitors such as OECs. Moreover, VEGF-
A was the predominant ligand expressed by OFT-ECs, 
whereas PLGF was the predominant ligand expressed 
by noncardiac OECs. PLGF binds to KDR with a higher 
affinity than VEGF-A, indicating that the differential ex-
pression of different members of the VEGF family may 
also imply a functional difference among ECs derived 
from various organ systems. Our results are also consis-
tent with another study that reports that cardiac ECs may 
have better angiogenic properties than noncardiac ECs 
[34]. Retroviral gene delivery of Isl1 to ECs enhances 
their angiogenic properties including augmentation in 
proliferation of ECs, adhesion to fibronectin, secretion of 
IL-1β and VEGF, migratory index and vascular density 
in the matrigel plug in vivo when compared with the un-
treated control [34]. 
Chemically modified VEGF mRNA promotes heart pro-
gentior vascularization, proliferation and survival fol-
lowing transplantation
To directly examine the role of VEGF-A in driving en-
dothelial specification of the cardiovascular progenitors 
in vivo, we utilized a novel modRNA delivery approach 
to mediate highlyefficient expression of autocrine factors 
by the Isl1
+ progenitors. In vivo transgene delivery that 
utilizes naked DNA plasmids or engineered viral vectors 
has limited efficacy and safety with low transfection ef-
ficiency, uncontrollable dose release, antiviral immunity 
and some risk of genome recombination or insertional 
tumorigenesis, whereas delivery of recombinant proteins 
also has other problems including short protein half-life 
[35-38]. On the other hand, chemical modification with 
the replacement of uridine and cytidine with 2-thiouri-
dine and 5-methylcytidine, respectively, facilitates 
in vivo delivery of mRNA by increasing stability and 
avoiding activation of the innate immunity commonly 
associated with transcribed mRNA [23, 24]. The VEGF-
A modRNA has been demonstrated in a parallel study 
in vivo with proangiogenic effect when directly injected 
intramuscularly into infarcted hearts [17]. The VEGF-
A modRNA directs expansion and differentiation of the 
epicardial progenitors toward an EC fate, and triggers 
regeneration of the heart following MI via increased 
angiogenesis, reduced fibrosis and post-infarct remodel-
ing, and increased survival of the recipients for at least 1 
year following a single injection of modRNA. With the 
success of this parallel study, we reasoned that VEGF-
A modRNA could also represent an improved gene de-
livery platform to direct cell fate decision of the human 
cardiovascular progenitors in vivo. Human Isl1
+ progeni-
tors were implanted subcutaneously in the vehicle- or 
VEGF-A modRNA-containing matrigel in NOD/SCID 
mice for 2 weeks. Our results reveal that there were more 
SMMHC
+/Vimentin
+ smooth muscle-like structures in 
the vehicle-treated group than the VEGF-A modRNA-
treated group, whereas more CD31
+ microvessel-like 
structures were found in the VEGF-A modRNA-treated 
group than the vehicle-treated group. Taken together, 
our result has demonstrated a direct effect of VEGF-A in VEGF-A mRNA promotes cell-fate switch of heart progenitors
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driving endothelial specification of the human Isl1
+ car-
diovascular progenitors both in vitro and in vivo, away 
from the spontaneous smooth muscle and cardiac muscle 
differentiation pathways (Figure 6D). Moreover, VEGF-
A can also promote proliferation and reduce apoptosis 
of the engrafted cells. Hence, it will be of interest to 
determine whether driving vascularization using human 
pluripotent stem cell-derived endothelial progenitors will 
have beneficial effects in the setting of cardiac injury. In 
addition, future studies would be warranted to determine 
whether transfection of VEGF-A modRNA into other 
tissue-specific progenitors may enhance their capability 
to engraft and survive in disease models of other solid 
organs.
Materials and Methods
Human ESC culture, EC differentiation and flow cytometry
The human Isl1-cre eGFP lineage-tracing ESC line was engi-
neered and maintained as described previously [16]. To generate 
ECs via formation of EBs, a sequential administration of cytokines 
was implemented. Briefly, human ESCs were treated with 0.5 
mg/ml dispase (Gibco) and then suspended in six-well ultra-low 
cluster plates (Costar) with human ESC differentiation medium 
containing DMEM/F12 (Gibco) supplemented with 10% knockout 
serum replacement (KOSR, Invitrogen), 1× non-essential amino 
acids (Gibco), 1× l-glutamine (Invitrogen), 1× penicillin/strepto-
mycin (Invitrogen) and 1× β-mercaptoethanol (Gibco). On day 0, 
medium was supplemented with 20 ng/ml BMP4 (R&D Systems) 
(removed on day 7); on day 1, medium was supplemented with 10 
ng/ml activinA (R&D Systems) (removed on day 4) and on day 4, 
EBs were transferred to adherent, Matrigel-coated plates with hu-
man ESC differentiation medium containing 1% KOSR and 8 ng/
ml FGF-2 (Peprotech) (removed on day 7). From day 4 onwards, 
cells were incubated in hypoxia (5% oxygen). On day 7, cultures 
were dissociated using 0.25% Trypsin (Gibco) and the eGFP
+ 
cells were purified using FACSAriaII (BD). eGFP
+ cells were 
then cultured in human ESC differentiation medium containing 
1% KOSR and 100 ng/ml VEGF-A (Peprotech) until the indicated 
time points. ECs were stained with fluorochrome-conjugated anti-
CD31, anti-CD34, anti-CD105, anti-CD133, anti-CD144, anti-
Flt1, anti-KDR, anti-Flt4, and anti-CXCR4 antibodies (BD), and 
then purified or analyzed using FACSAriaII. To generate cells for 
clonal assays, cells on day 7 were dissociated into single cells us-
ing 0.25% trypsin-EDTA and stained with propidium iodide (PI, 
BD) to exclude dead cells for sorting on the FACSAriaII. The pu-
rified eGFP
+PI
− cells were plated on 24-well plates with irradiated 
MEF feeders and cultured in human B27 medium supplemented 
with 100 ng/ml VEGF-A. After 5 days of culture, colonies were 
picked for RNA isolation. 
Isolation of ECs from human fetal hearts and human cord 
blood
Human fetal hearts and umbilical cords (from authorized re-
sources) were dissociated to achieve a single-cell suspension by 
collagenase II (Sigma-Aldrich), OFT-ECs were isolated by FACS 
[39] via costaining with anti-CD31 and anti-CD144 antibodies 
(BD), and the double positive cells were purified using FACSAri-
aII. Viability dyes including PI or DAPI was also used to exclude 
dead cells. OECs were isolated by differential plating as described 
previously [40-42]. OECs expressed EC-specific surface markers, 
including CD31, CD144, CD146 vWF and VEGFR-2, and could 
improve peripheral perfusion in a murine hindlimb ischemia mod-
el [41]. OFT-ECs, OECs and HMVECs were cultured in EGM2 
medium (Lonza). 
Preparation of the modRNA for in vitro and in vivo trans-
fection
Production of in vitro transcription template constructs (Supple-
mentary information, Table S1) and subsequent mRNA synthesis 
has been described previously [24]. Briefly, open reading frames 
were amplified by PCR from plasmids encoding mCherry or hu-
man VEGF-A (165) (Addgene). RNA was synthesized with the 
MEGAscript T7 kit (Ambion), and a custom ribonucleoside blend 
was used comprising 3′-O-Me-m7G(5′)ppp(5′)G cap analog (New 
England Biolabs), adenosine triphosphate and guanosine triphos-
phate (USB), 5-methylcytidine triphosphate and pseudouridine tri-
phosphate (TriLink Biotechnologies). For transfection, modRNA 
and RNAiMAX transfection agent were each dissolved separately 
in Opti-MEM (Invitrogen), combined, and then incubated for 15 
min at room temperature to generate a transfection mixture. In vi-
tro transfection was performed by adding the transfection mixture 
(1 µg modRNA) to cells plated in DMEM supplemented with 2% 
FBS and 200 ng/ml B18R (eBioscience) or in Pluriton Reprogram-
ming Medium (Stemgent). Repeated transfections could be per-
formed after medium change in cultures. In vivo transfection was 
performed by adding the transfection mixture (5 µg modRNA) 
directly into the cell-containing matrigel before s.c. implantation 
into NOD/SCID mice (Jackson lab). 
RNA isolation and gene expression profiling
Total RNA was isolated from purified cells of different groups 
using the RNeasy mini kit (Qiagen) and reverse transcribed using 
Superscript III RT (Invitrogen), according to the manufacturers’ 
instructions. Real-time qPCR profiling was performed using the 
angiogenesis growth factor expression arrays (SA Biosciences) 
analyzed on Mastercycler realplex 4 Sequence Detector (Ep-
pendoff) via SYBR Green (QuantitectTM SYBR Green PCR Kit, 
Qiagen). The relative gene expression level of each sample was 
expressed as a relative quantitation (RQ) value determined by 
the 2
−ddCT method that represents the fold change in gene expres-
sion normalized to the housekeeping gene, Gapdh. The relative 
gene expression level of each sample was also compared with an 
internal control. Complementary DNA PCR primer sequences are 
shown in Supplementary information, Table S2. 
Immunohistochemistry
Human fetal hearts were obtained from authorized sources and 
the pericardium was removed. Human fetal hearts, matrigel plugs 
or teratoma samples were freshly fixed in 4% paraformaldehyde at 
4 °C overnight. The hearts were washed four times with PBS at 
4 °C and equilibrated in 30% sucrose before freezing and cryosec-
tioning. Six micrometer sections were blocked at 2% goat serum 
and then stained with different primary antibody combinations at 
10 µg/ml at 4 °C overnight. Primary antibodies used for staining 
are: mouse anti-ISL1 (Developmental Studies Hybridoma Bank), www.cell-research.com | Cell Research
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rabbit anti-cTNT, rabbit anti-CD31, rabbit anti-CD144, chicken 
anti-eGFP, rabbit anti-Flt1, mouse anti-SMMHC, rabbit anti-vWF 
(Abcam), mouse anti-Ki67 (BD), rabbit anti-KDR/Flk1 (Upstate) 
and mouse anti-Vimentin (R&D systems) antibodies. Alexa-
Fluor-488- or Alexa-Fluor-594-conjugated secondary antibodies 
(Molecular Probes) were used for 30 min at room temperature, and 
500 µg/ml of DAPI (Vector Labs, US) was used at room tempera-
ture for 5 min in the dark. Slides were mounted with fluorescence 
mounting medium (Dako, US) and allowed to dry at 4 °C over-
night in the dark. For the TUNEL assay, an in situ cell death detec-
tion kit, fluorescein (Roche) was used according to manufacturer’s 
instructions. Fluorescence was detected with the laser scanning 
confocal microscope (Zeiss, Germany) and quantification of the 
immunostaining images was performed by the blind cell counts 
(10-20 sections or > 1 000 cells per group) using the ImageJ soft-
ware. 
Tube formation assay
Fifteen thousand to twenty thousand of GFP
+CD31
+CD144
+ 
ECs differentiated from Isl1-cre eGFP human ESCs were cultured 
in 50 µl of matrigel (BD) and 200 µl of EGM2 medium (Lonza) 
in each well of a 96-well plate overnight. Three dimensional tubes 
were visualized and fluorescence images were taken next day un-
der the laser scanning confocal microscope.
In vivo matrigel plug assay and matrigel cytometry
All animal procedures were performed in accordance with pro-
tocols approved by the Massachusetts General Hospital. FACS-
purified, day-7 eGFP
+ cells derived from the Isl1-cre eGFP human 
ESC line were resuspended in the vehicle- or VEGF-A modRNA 
(1 µg/10
6 cells)-supplemented matrigel and were then s.c. injected 
into the NOD/SCID mice (n = 5 for each group). The matrigel 
plugs were harvested 1-2 weeks post implantation. Human ECs 
from matrigel plugs can be isolated for FACS analyses as de-
scribed previously [25]. Matrigel plugs were incubated for 1 h 
at 37 °C in PBS supplemented with 25 μg/ml hyalurinidase (MP 
biomedical), 25 μg/ml DNase (Sigma), 3 unit/ml Dispase and 3 
unit/ml Liberase (Roche). The isolated cells were filtered using a 
40 μm nylon mesh (BD), washed three times with FACS buffer 
(PBS supplemented with 1% BSA) and were subsequently stained 
with pacific blue-conjugated anti-CD31 and APC-conjugated anti-
CD144 antibodies (BD) for FACS analyses. Viability dyes includ-
ing PI or DAPI were also used to exclude dead cells for sorting.
Statistical analyses
The data were expressed as arithmetic mean ± SD of triplicate 
determinations performed under the same conditions. Statistical 
analysis was performed using the Student’s t-test (*P < 0.05, **P 
< 0.01, ***P < 0.001).
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